Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 40

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 40
---
, with the remainder thereafter. The contract liabilities of $32.7 million and $33.2 million as of June 30, 2025 and December 31, 2024, respectively, consisted of deferred revenue related to extended warranty service agreements.The following revenue recognized for the periods indicated were included in deferred revenue as of December 31, 2024 and 2023, respectively (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Deferred revenue recognized$5,046 $3,146 $10,903 $6,741 The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company’s Visium and Xenium products:Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024InstrumentsChromium$5,727 $8,792 $11,640 $16,642 Spatial8,770 15,060 17,672 32,663 Total instruments revenue14,497 23,852 29,312 49,305 ConsumablesChromium85,788 94,108 169,897 178,035 Spatial36,397 29,254 67,644 55,662 Total consumables revenue122,185 123,362 237,541 233,697 Services8,475 5,776 16,127 10,993 Products and services revenue145,157 152,990 282,980 293,995 License and royalty revenue27,751 114 44,811 115 Total revenue$172,908 $153,104 $327,791 $294,110 

12

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024AmericasUnited States(1)$103,491 $89,672 $190,309 $165,309 Americas (excluding United States)2,667 3,419 6,419 7,412 Total Americas106,158 93,091 196,728 172,721 Europe, Middle East and Africa34,734 37,